A Randomized, Two-Period, Two-Arm, Double-Dummy, Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide in Patients With Heart Failure (NEXT-HF)
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Urinary sodium excretion measurement
研究概览
简要总结
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic.
The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
详细描述
Research Plan
Study Design
This is a double-blind, double-dummy, two-period, two-arm, randomized, crossover study.
Initial Study Procedures
Identification of Participants: Patients with a known history of stable heart failure (HF) for at least one month will be identified through healthcare records at clinical site, heart failure clinic, nephrology clinic, and other relevant clinics.
研究设计
- 研究类型
- 干预性
- 分配方式
- 随机
- 干预模型
- 交叉
- 主要目的
- 治疗
- 盲法
- 四盲 (受试者、医护人员、研究者、结局评估者)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- Age: 18 years or older.
- Informed Consent: Willing and able to sign the informed consent form.
- Stable Chronic HF: A clinical diagnosis of chronic heart failure considered stable by the patient's cardiologist/physician or another experienced clinician for at least one month prior to randomization.
- Current Diuretic Therapy: Receiving an oral dose of 20 mg to 80 mg daily of furosemide, or 10 mg to 40 mg daily dose of torsemide, or 1 mg to 4 mg daily dose of bumetanide, for about 30 days prior to randomization.
- Stable HF Medications: No anticipated changes in HF medications during the study period.
- Female Participants: Premenopausal women of childbearing potential must have a negative pregnancy test prior to study initiation and agree to use effective contraceptive methods throughout the study period.
排除标准
- Other Diuretics: Requirement for a diuretic other than furosemide, bumetanide, or torsemide (except for spironolactone, eplerenone, finerenone, or SGLT2 inhibitors) at randomization or during the study.
- Recent Cardiovascular Events: Myocardial infarction, stroke, transient ischemic attack, acute kidney injury, or acute HF requiring hospitalization within 30 days prior to randomization.
- Severe Lung Disease: Severe or symptomatic lung disease or respiratory symptoms distinct from HF.
- Urinary Issues: History of urinary incontinence, or inability to empty the bladder.
- Uncontrolled Comorbidities: Uncontrolled diabetes mellitus or hypertension.
- Renal Dysfunction: Estimated GFR < 30 ml/min/1.72m².
- Cardiac Conditions: History of flash pulmonary edema or amyloid cardiomyopathy.
- Breastfeeding: Female participants who are breastfeeding.
- Recent Participation in Clinical Trials: Participation in another clinical trial within the last three months prior to randomization.
- Requirements for treatment with a non-steroidal anti-inflammatory drug (except for Aspirin up to 200 mg as PRN daily).
- Serum potassium concentration <3.5 or >5.5 mmol/L.
研究组 & 干预措施
Arm 1 IR torsemide
Approximately half of the participants will receive 20 mg IR torsemide followed by 24 mg ER torsemide or 40mg IR torsemide followed by 48 mg ER torsemide (6-10 days each)
干预措施: Extended Release Torsemide Tablets (Drug)
Arm 1 IR torsemide
Approximately half of the participants will receive 20 mg IR torsemide followed by 24 mg ER torsemide or 40mg IR torsemide followed by 48 mg ER torsemide (6-10 days each)
干预措施: Immedate Release Torsemide Tablets (Drug)
ARM 2 ER torsemide
The other half will receive 24 mg ER torsemide followed by 20 mg IR torsemide, or 48 mg ER torsemide followed by 40 mg IR torsemide (6-10 days each)
干预措施: Extended Release Torsemide Tablets (Drug)
ARM 2 ER torsemide
The other half will receive 24 mg ER torsemide followed by 20 mg IR torsemide, or 48 mg ER torsemide followed by 40 mg IR torsemide (6-10 days each)
干预措施: Immedate Release Torsemide Tablets (Drug)
结局指标
主要结局
Urinary sodium excretion measurement
时间窗: 4-8 hours (post-lunch period)
Urinary sodium excretion (mmol) measured after dosing: 4-8 hours (post-lunch period)
次要结局
- Urinary sodium excretion(0-4 hours (pre-lunch period) and 8-24 hours (post-lunch period))
研究者
研究点 (1)
标识符
- NCT 编号
- NCT06995144
- 其他研究编号
- SAR-2025-019
日期
- 首次提交
- (去年)
- 首次发布
- (去年)
- 主要完成日期
- (14天前)
- 研究完成日期
- (14天前)
- 最近核实
- (29天前)
- 最近更新
- (前天)
监管与共享
- FDA 监管药物
- 是
- FDA 监管器械
- 否
- 个体参与者数据共享计划
- UNDECIDED
- 是否有结果
- 否
HIPAA